Sou Hu Cai Jing·2025-08-31 00:50Core Viewpoint - The company Zhaoyan New Drug announced its intention to establish a seed fund in partnership with Yifeng Capital and Yifeng Mingyuan, focusing on investments in the biomedicine and high-end medical device sectors, with a total fundraising target of 12.75 million RMB [2][3]. Group 1: Company Overview - Zhaoyan New Drug, founded in 1995, is a specialized contract research organization (CRO) headquartered in Beijing, with over 2,500 professionals across multiple locations including Beijing, Suzhou, and the United States [3][4]. - The company is listed on both A-share and Hong Kong stock markets, categorized as an "A+H" enterprise [4]. Group 2: Investment Details - The seed fund will have a total fundraising scale of 12.75 million RMB, with Zhaoyan New Drug or its designated subsidiary committing up to 10 million RMB as a limited partner (LP) [2]. - The fund aims to support strategic emerging industries and key sectors prioritized by the Shenzhen government, particularly in biomedicine and high-end medical devices [3]. Group 3: Partner Information - Yifeng Capital, established in 2012, focuses on investments in the biomedicine sector and is recognized as one of the top venture capital institutions in Shenzhen [2][3]. - The investment portfolio of Yifeng Capital includes several successful companies that have gone public, such as Microchip Biotech and Apexigen [3].